GlassScriptPhysician profile
Rafael Miret
NPI 1114489416
$2,264.45
in general payments reported to CMS, 2019-2025
9 companies · $770 in 2025
The $770 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $119 · 2021: $211 · 2022: $121 · 2023: $656 · 2024: $387 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313 · Grant: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.06 |
| Grant | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $692.66 | 2023-2025 | |
| Glaxosmithkline, LLC. | $466.32 | 2022-2024 | Arexvy |
| Actelion Pharmaceuticals US, INC. | $288.30 | 2024-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $247.66 | 2023-2024 | Fasenra |
| Abbvie INC. | $228.33 | 2020-2021 | |
| Insmed, INC. | $124.99 | 2023 | |
| Mallinckrodt Hospital Products INC. | $113.88 | 2023 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.58 | 2021 | |
| Boston Scientific Corporation | $17.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Miret listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.